ANSTO Publications Online

Welcome to the ANSTO Institutional Repository known as APO.

The APO database has been migrated to version 7.5. The functionality has changed, but the content remains the same.

ANSTO Publications Online is a digital repository for publications authored by ANSTO staff since 2007. The Repository also contains ANSTO Publications, such as Reports and Promotional Material. ANSTO publications prior to 2007 continue to be added progressively as they are in identified in the library. ANSTO authors can be identified under a single point of entry within the database. The citation is as it appears on the item, even with incorrect spelling, which is marked by (sic) or with additional notes in the description field.

If items are only held in hardcopy in the ANSTO Library collection notes are being added to the item to identify the Dewey Call number: as DDC followed by the number.

APO will be integrated with the Research Information System which is currently being implemented at ANSTO. The flow on effect will be permission to publish, which should allow pre-prints and post prints to be added where content is locked behind a paywall. To determine which version can be added to APO authors should check Sherpa Romeo. ANSTO research is increasingly being published in open access due mainly to the Council of Australian University Librarians read and publish agreements, and some direct publisher agreements with our organisation. In addition, open access items are also facilitated through collaboration and open access agreements with overseas authors such as Plan S.

ANSTO authors are encouraged to use a CC-BY licence when publishing open access. Statistics have been returned to the database and are now visible to users to show item usage and where this usage is coming from.

Contact the Repository

 

Communities in ANSTO Publications Online

Select a community to browse its collections.

Now showing 1 - 5 of 5

Recent Submissions

No Thumbnail Available
Item
Biodistribution of a boronated porphyrin in BC-1 mammary carcinoma
(Plenum Press, 1993) Mallesch, JL; Moore, DE; Kahl, SB; Thorne, R; Allen, BJ
Breast cancer is the most common invasive neoplasm and the second most common cause of death from cancer in women. In breast cancer, local control is a function not only of the size of the tumour but also of associated features, e.g. satellite nodules, and a great majority of patients die with disseminated disease. For many years the standard treatment for breast cancer has been surgery, coupled with post-operative radiotherapy and chemotherapy, where indicated. The use of radiotherapy has reduced the incidence of recurrence but there has been little effect on survival rates. Chemotherapy is also used to treat recurrent breast cancer but the use of these drugs has inherent problems. © Plenum Press
No Thumbnail Available
Item
The biodistribution of p-boronophenylalanine-fructose in human patients with glioma and metastatic melanoma
(Plenum Press, 1993) Mallesch, JL; Moore, DE; Allen, BJ; McCarthy, WH; Jones, R; Stening, WA
Modern diagnostic techniques and the introduction of radiotherapy and chemotherapy have not improved the prognosis for certain cancers where life expectancy after diagnosis is less than 12 months. High grade brain tumours and metastatic melanoma to the brain fall into this category. Their common feature of infiltrating malignant cells contraindicates curative surgery and radiotherapy. © Plenum Press
No Thumbnail Available
Item
Ftir spectrometry for the assay of polyhedral boron compounds in plasma
(Plenum Press, 1993) Moore, DE; Setiawan, Y; Blagojevic, N; Allen, BJ
Many of the new compounds being developed for neutron capture therapy contain the icosahedral boron cage structure with up to 12 boron atoms. The infrared spectrum of each compound provides a fingerprint which can be used as an aid in their identification.1 In particular, the most intense and identifiable band is the boron-hydrogen stretching vibration at about 2500 cm-1. This high energy region is relatively free from overlap due to absorption by solvent and other molecules in the system. Additionally, the B-H stretch band is not significantly influenced by interaction from the surrounding atoms. The advent of Fourier Transform infrared instrumentation (FTIR) has enhanced the capabilities of this spectroscopic technique, especially in the area of sensitivity and speed of assay. Thus FTIR is used routinely, for example to confirm the introduction of the boron cluster in the synthesis of new polyhedral boron compounds,2 and in characterising reconstituted boronated low density lipoproteins.3 Very recently, FTIR was applied to the determination of sodium borocaptate (BSH) in aqueous solution and urine. © Plenum Press
No Thumbnail Available
Item
An intra-pancreatic and hepatic nude mouse cancer xenograft model for boron neutron capture therapy
(Plenum Press, 1993) Mallesch, JL; Chiaraviglio, D; Allen, BJ; Moore, DE
The cure of many cancers depends on their early detection and surgical excision. This is not the case for primary pancreatic cancer and hepatic metastases which have very poor prognoses. Cancer cells infiltrate the liver and current treatment protocols are unable to selectively kill these cells. Even though the affected organs are deep seated in the patient, NCT with an epithermal beam of the appropriate characteristics, used externally or intra-operatively, might represent an approach to the treatment of the cancers. In the development of an animal model system, the subcutaneous inoculation of pancreatic and hepatic tumour cell lines into nude mice has many limitations. An alternative approach is to inoculate internal organs with cancer cells to produce a different, but potentially more realistic, behaviour of that tumour type. This may then provide a superior indication of the potential for targeting these cancers with boron compounds. © Plenum Press
No Thumbnail Available
Item
Histological examination of murine melanoma xenografts in the nude mouse model: pre and post neutron capture therapy
(Plenum Press, 1993) Mallesch, JL; Crotty, K; Moore, DE; Allen, BJ
Boron neutron capture therapy combines elements of radiotherapy and chemotherapy in order to achieve the selective irradiation of tumour tissue. A non-toxic boron compound with affinity for the tumour is combined with thermal neutrons to achieve selective tumour kill amongst normal tissue cells. © Plenum Press